LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announces its schedule for the publication of financial information for 2016.
| Event | Date * | |||||
| 2015 Full-Year Sales | January 28, 2016 – After market closes | |||||
| 2015 Full-Year Financial Statement | March 31, 2016 – After market closes | |||||
| 2016 Q1 Sales | May 5, 2016 – Before market opens | |||||
| 2016 Q2 Sales | July 15, 2016 – Before market opens | |||||
| 2016 June 30th, Financial Statement | September 12, 2016 – Before market opens | |||||
| 2016 Q3 Sales | October 21, 2016 – Before market opens | |||||
| 2016 Full-Year Sales | January 27, 2017 – Before market opens | |||||
|
|
||||||
About Poxel
Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has started Phase 2b development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160103005058/en/
Investor relations / Media - EU/US
MacDougall Biomedical
Communications
Gretchen Schweitzer, +49 89 2424 3494
or
Stephanie
May, +49 172 861 8540
smay@macbiocom.com
or
Investor
relations / Media – France
NewCap
Florent Alba / Nicolas
Mérigeau, +33 1 44 71 98 55
poxel@newcap.eu
Source: POXEL SA
Released January 4, 2016